

Supp. Table 1. Iwanowycz et al. (2015)

Supplemental table 1. Antibodies used for western blots and ChIP procedures

Antibodies	Procedure	Product #	Company
p65	Western	8242	Cell Signaling
STAT1	Western	sc-346	Santa Cruz
STAT6	Western	9362	Cell Signaling
IRF4	Western	sc-6059	Santa Cruz
IRF5	Western	4950	Cell Signaling
Actin	Western	A2066	Sigma
TBP	Western	ab51841	Abcam
H3K27m3	ChIP	ab6002	Abcam
H3K27m3	Western	07-449	Millipore
H3K27ac	Western/Chip	AB4729	Abcam
H3	Western	05-928	Millipore
Anti-rabbit HRP	Western	sc-2004	Santa Cruz
Anti-Mouse HRP	Western	sc-2005	Santa Cruz
Anti-goat HRP	Western	sc-2024	Santa Cruz

Supp. Table 2. Iwanowycz et al. (2015)

Supplemental Table 2. Primers used for RT-qPCR

Primers	Forward	Reverse
18s	CGCGGTTCTATTTTGTGGT	AGTCGGCATCGTTTATGGTC
TNF	CGT CAG CCG ATT TGC TAT CT	CGG ACT CCG CAA AGT CTA AG
CXCL2	CGCTGTCAATGCCTGAAG	GGCGTCACACTCAAGCTCT
CXCL10	TGAATCCGGAATCTAAGACCATCAA	AGGACTAGCCATCCACTGGGTAAAG
MRC1	TGGATGGATGGGAGCAAAGT	AATGCCAACCTTCCTTGCAG
IRF5	CAGGTGAACAGCTGCCAGTA	CTCATCCACCCCTTCAGTGT
SOCS1	TTAACCCGGTACTCCGTGAC	GAGGTCTCCAGCCAGAAGTG
CCL2	CAGGTCCCTGTCATGCTTCT	TCTGGACCCATTCTTCTTG
IL1b	GCCATCCTCTGTGACTCAT	AGGCCACAGGTATTTTGTCTG
INOS	CACCTTGAGTTCACCCAGT	ACCACTCGTACTTGGGATGC
IL6	AGTTGCCTTCTTGGGACTGA	TCCACGATTTCCAGAGAAC
TLR4	GCTTTCACCTCTGCCTTAC	GAAACTGCCATGTTTGAGCA
MMP2	ACACTGGGACCTGTCACTCC	GCGAAGAACACAGCCTTCTC
MMP9	CATTCGCGTGGATAAGGAGT	ACCTGGTTCACCTCATGGTC
Arg1	TTTTTCCAGCAGACCAGCTT	GGAACCCAGAGAGAGCATGA
Chi313	TGGAATTGGTGCCCCTACAA	CCACGGCACCTCCTAAATTG
IRF4	GCAGCTCACTTTGGATGACA	CCAAACGTCACAGGACATTG
CSFr1	TTGGACTGGCTAGGGACATC	GGTTCAGACCAAGCGAGAAG
CDKNn1a	CAAAGTGTGCCGTTGTCTCT	AGGAAGTACTGGGCCTCTTG

Supp. Table 3. Iwanowycz et al. (2015)

Supplemental Table 3. Primers used for CHIP-PCR. P-promoter

	Forward	Reverse	Region	IP
INOS-1	TCCCTAGTGAGTCCCAGTTTTGA	CTGGTCGCCC GTCCAAGG	P	H3K27m3
INOS-2	GCGCTCTAGTGAAGCAAAGG	TCTTAGTGGCC CAGGACAAG	CpG	H3K27ac
TNF	AGGAGAAGGCTTGTGAGGTC	GAGTTGGGAAGTGTGCATGG	P	H3K27m3
IL6	AGGAGTGTGAGGCAGAGAGC	GTCTCCTCTCCGGACTTGTG	Intron	H3K27m3
IRF4	CACGTGATGGTCTCTGGTTG	TCATCCCACTTTTCCCTCAC	P	H3K27m3, H3K27ac
ARG1-1	TGAACAGGCTGTATTAGCCAACA	AGCACCCCTCAACCCAAAGTG	P	H3K27m3
ARG1-2	AGTTCCTCTGATGGGGAGGT	TCATGCTCTCTCTGGGTTC	P	H3K27ac
YM1	ACTTGCAACTACTCTGCACT	ACACCCCTGAGCTTTGGTAA	P	H3K27m3, H3K27ac

Supp. Table 4. Iwanowycz et al. (2015)

Supplemental Table 4. Genes that were inversely regulated by emodin under the two different treatments. Column 2 lists the fold change of the LPS/IFN γ +emodin group compared to the LPS/IFN γ group. Column 3 lists fold change of IL4+emodin compared to IL4 treatment. Red=increased expression; green=repressed expression.

Gene	Em+LPS vs LPS/IFN	Em+IL4 vs IL4
Rab3il1	2.66	-16.18
Mrgprg	2.18	-16.05
Gprc5c	3.74	-8.77
Ikzf2	3.42	-6.36
Kctd12b	3.62	-5.06
Ear1	2.04	-4.71
Jakmip1	9.59	-4.67
Trim45	4.00	-4.60
Snn	2.13	-4.52
Chi3l3	2.04	-4.24
Cmb1	5.87	-4.21
Ubtf	2.47	-4.20
Xpo7	2.41	-4.00
Ear2	2.03	-4.00
Gpr77	3.05	-3.71
Mnt	2.31	-3.70
Gm4610	8.80	-3.53
Igf1	2.12	-3.47
Armcx6	2.81	-3.43
S100a4	3.02	-3.36
Islr2	3.58	-3.34
Sult1a1	2.95	-3.15
9230110K08Rik	3.15	-2.88
Senp8	2.13	-2.88
Zfp473	3.06	-2.82
Itga4	4.86	-2.82
Cables1	3.87	-2.76
Klf11	2.47	-2.74
A930006K02Rik	2.18	-2.72
BC031361	2.05	-2.68
6430531B16Rik	2.25	-2.65
Taf6l	2.04	-2.62

Nudt16l1	2.01	-2.59
Tbc1d16	3.26	-2.57
Scgb2b27	2.23	-2.56
BC025920	2.91	-2.51
Ccl9	5.28	-2.48
Bcl9	2.64	-2.43
1700097N02Rik	2.01	-2.42
Gzmm	3.64	-2.40
Ear11	3.20	-2.39
Hfe	3.09	-2.36
AW555355	2.31	-2.34
D230044B12Rik	2.39	-2.30
Mrc1	8.72	-2.29
Rassf2	2.62	-2.29
Acp5	2.02	-2.22
Inpp5j	5.52	-2.21
AA914427	3.21	-2.20
A430110L20Rik	2.47	-2.19
Metrn1	2.02	-2.19
Gm9484	3.19	-2.13
Gdf3	3.34	-2.12
Selp	3.09	-2.08
Ier5l	3.05	-2.04
Cdk14	-2.71	2.03
3930401B19Rik	-2.72	2.04
Tgfb1	-3.22	2.06
Cpd	-2.21	2.06
Fzd1	-2.45	2.08
Klra2	-14.35	2.10
Prkar2b	-4.32	2.12
Apol9a	-4.48	2.16
Chpt1	-4.06	2.20
Ass1	-6.11	2.22
Slc7a3	-3.03	2.23
Gm20186	-2.65	2.26
Procr	-2.07	2.38
Ppap2b	-2.13	2.55
Ptgs2	-3.99	2.56
Tnf	-2.01	2.69
Clec4n	-2.63	2.94
Smtnl2	-4.06	2.96

Thbs1	-6.51	3.22
Jag1	-11.28	3.54
Dusp14	-3.14	3.62
Hmga2	-2.02	3.79
Pla2g5	-4.28	4.26
Flrt3	-4.09	4.37
Cck	-25.26	4.53
Serpine1	-23.78	6.13
Clec9a	-4.62	7.13
Cxcl3	-37.91	7.37
Tnfaip6	-16.37	9.27
Cxcl10	-10.31	15.05
Cxcl2	-2.47	60.63

Supp. Table 5. Iwanowycz et al. (2015)

Supplemental table 5. Histone modifying enzymes significantly changed by emodin compared to LPS/IFN γ (top) or IL4 (bottom) treatment

Histone modifying enzymes changed by emodin		
	LPS	LPS+Em
EZH1	N.C.	6.63
EZH2	N.C.	2.73
Hdac1	N.C.	-2.30
Hdac8	N.C.	-4.08
KAT2B	2.33	-4.69
KAT6B	-2.41	3.65
KDM3B	N.C.	2.12
KDM4A	N.C.	9.21
NCOA3	N.C.	2.58
NSD1	-2.06	2.46
PHF8	-2.35	3.62
PRDM2	2.18	3.78
SETD1B	N.C.	2.09
SETD7	N.C.	2.06
Sirt5	-2.06	-4.41
Sirt7	N.C.	2.06
SMYD2	N.C.	-3.02
SUV420H1	N.C.	3.06
Mll1	N.C.	3.09
	IL4	IL4+Em
EZH1	N.C.	-6.26
EZH2	N.C.	-2.04
Hdac1	N.C.	2.32
Hdac8	N.C.	2.33
Hdac9	N.C.	4.39
KAT2B	N.C.	3.81
KAT6B	N.C.	-2.70
KDM2A	N.C.	2.04
KDM4A	N.C.	-7.58
KDM4B	N.C.	2.11
KDM5B	N.C.	-2.13
KDM6B	-2.20	1.91
Mll1	N.C.	-2.20

Mll2	N.C.	-2.64
NCOA2	N.C.	2.60
PHF8	N.C.	-5.60
PRDM2	N.C.	-2.26
Sirt7	N.C.	-2.30
SMYD3	N.C.	-2.79
SUV420H1	N.C.	-2.46